Return On Capital Employed Overview: Akebia Therapeutics

During Q3, Akebia Therapeutics AKBA brought in sales totaling $59.99 million. However, earnings decreased 66.58%, resulting in a loss of $58.09 million. In Q2, Akebia Therapeutics brought in $90.14 million in sales but lost $173.82 million in earnings.

What Is ROCE?

Changes in earnings and sales indicate shifts in Akebia Therapeutics's Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q3, Akebia Therapeutics posted an ROCE of -0.18%.

It is important to keep in mind ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but several factors could affect earnings and sales in the near future.

Return on Capital Employed is an important measurement of efficiency and a useful tool when comparing companies that operate in the same industry. A relatively high ROCE indicates a company may be generating profits that can be reinvested into more capital, leading to higher returns and growing EPS for shareholders.

For Akebia Therapeutics, the return on capital employed ratio shows the current amount of assets may not actually be helping the company achieve higher returns, a note many investors will take into account when making long-term financial decisions.

Q3 Earnings Insight

Akebia Therapeutics reported Q3 earnings per share at $-0.42/share, which did not meet analyst predictions of $-0.17/share.

Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsBZI-ROCE
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...